The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial

What this Trial Is About

Researchers are evaluating ways to reduce hypoxia, a common adverse reaction during sedation, in patients undergoing transvaginal oocyte retrieval procedures. This trial compares the rate of hypoxia when using a combination of remimazolam and alfentanil versus the commonly used propofol and alfentanil combination to improve patient safety and reduce perioperative complications. The study is a multicenter, prospective, randomized, controlled clinical trial led by Diansan Su. Participants will receive sedation with either the remimazolam-alfentanil combination or the propofol-alfentanil combination. The remimazolam group is given 7 µg/kg of fentanyl first, followed by remimazolam 0.2 mg/kg as a 1-minute bolus, then a continuous infusion at 1 mg/kg per hour. The propofol group receives 7 µg/kg of fentanyl first, then propofol 2 mg/kg as a 1-minute bolus, followed by a 6 mg/kg per hour infusion. Both sedation methods are used during the transvaginal oocyte retrieval procedure. Participants will be monitored throughout their hospital stay, expected to last about two hours, to assess the incidence of hypoxia and related respiratory events. The study will record the occurrence of hypoxia, severe hypoxia, subclinical respiratory depression, and the use of measures to correct hypoxia. Safety and respiratory status will be closely followed during this period to compare the effects of the two sedation combinations.

The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval: A Multicenter Randomized Controlled Trial.